Common questions about Cortavance (FAQ)
Q: What is the key difference between Cortavance and an oral steroid for dogs?
A: Cortavance is a topical steroid designed specifically for application on the skin. Its active ingredient is structured to ensure low plasma availability, which means that once applied, it is rapidly absorbed into the skin layers for a local effect but is metabolized quickly before reaching the bloodstream in significant amounts. This localized action is intended to minimize the potential for systemic side effects commonly associated with oral corticosteroids.
Q: Can Cortavance be used for any kind of dog itching or skin inflammation?
A: Official product information states that Cortavance is indicated for the symptomatic treatment of inflammatory and pruritic dermatoses (itchy skin conditions) and to alleviate the clinical signs associated with atopic dermatitis in dogs. The medicine is authorized only for these specific classes of skin conditions, and a veterinarian will determine if it is appropriate for a specific cause of itching.
Q: How quickly should I expect to see an improvement in my dog's itching after starting Cortavance?
A: The official protocol specifies a daily treatment regimen. Regulatory labels indicate that for general dermatoses, treatment should be repeated for seven consecutive days. It is stated that the animal's condition should be re-evaluated by the veterinarian if no improvement is seen within 7 days of starting treatment.
Q: Is there a risk of systemic side effects like increased thirst or urination from Cortavance?
A: Official safety documentation notes that the potential for systemic corticosteroid effects is a very rare possibility, especially with misuse over a large body surface area or for prolonged periods. Although not explicitly listed, increased thirst and urination are classic symptoms associated with systemic corticosteroid excess.
Q: Why must underlying infections be treated before or alongside Cortavance?
A: Official labeling requires that concurrent microbial or parasitic skin diseases must be treated appropriately. This is because glucocorticoids are known to suppress the local immune response. Using the steroid without addressing an active infection may mask the signs or potentially allow the infection to worsen.
Q: Can Cortavance be used as part of a long-term maintenance treatment plan?
A: The authorized regimen for conditions like Atopic Dermatitis involves daily use for up to 28 consecutive days, followed by a required re-evaluation by the veterinarian to determine if continued use is necessary. Research evidence, however, provides limited insight into the effects and safety profile of the medicine beyond the initial study durations.
Q: Is there research available that compares Cortavance to other steroid topical sprays?
A: The primary research base provided for regulatory approval focuses on the medicine's efficacy against control or placebo groups. Official regulatory documents state that the product does not have available data regarding comparative claims vs other drugs.
Q: What does it mean that the active ingredient has 'low plasma availability'?
A: 'Low plasma availability' means the active ingredient is highly effective at penetrating the skin layers for a local anti-inflammatory effect but is quickly metabolized into inactive substances before reaching the general bloodstream in high amounts. This is intended to limit the drug's action to the treated skin area.
Q: Is the spray mechanism designed to prevent human hand contact with the medicine?
A: The product is provided as a volatile spray solution, and official instructions advise that the application does not require manual massage. This specialized application method facilitates the drug's efficacy without the need for physical contact between the hand and the medication.
Q: What happens if my dog licks the Cortavance spray off the application site?
A: Official instructions advise that treated animals should not be handled until the application site is dry. The active substance may be pharmacologically active if ingested in high amounts. Official instructions therefore advise that application should be managed to prevent ingestion, and that treated animals should not be handled until the application site is dry.
Q: Is it safe to spray Cortavance near sensitive areas like the dog's eyes or genitals?
A: Official precautions explicitly state that care should be taken to avoid spraying into the eyes of the animal. The product is intended for cutaneous use directly on the skin lesions as directed by a veterinarian.
Q: Can I apply Cortavance to areas of my dog's body that are covered by thick fur?
A: The solution is a volatile spray designed to disperse through the dog's coat and effectively penetrate the skin. Regulatory labeling indicates that no shaving is required for the medication to reach the skin surface, except potentially in cases of extremely long or matted hair.
Q: Does Cortavance work for 'hot spots' (Acute Moist Dermatitis)?
A: While the term 'hot spots' is a common name for Acute Moist Dermatitis, the official indication for Cortavance is for the symptomatic treatment of inflammatory and pruritic dermatoses. Since Acute Moist Dermatitis falls into this general category of skin conditions, a veterinarian may determine it to be an appropriate treatment.
Q: Why is Cortavance sometimes recommended for use with other allergy treatments?
A: The only specific restriction in official documents is to avoid the simultaneous application of other topical products on the same lesions. Regulatory documents state there is no data available regarding clinically relevant systemic drug interactions, which implies that co-administration with systemic allergy medications is not explicitly restricted.
